Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use

Circulation. 2018 Oct 9;138(15):1605-1607. doi: 10.1161/CIRCULATIONAHA.118.036862.

¹ Division of Cardiac Surgery, St. Michael's Hospital and University of Toronto, Ontario, Canada (S.V.).
² Division of Endocrinology and Metabolism, St. Michael's Hospital, and University of Toronto, Ontario, Canada (L.A.L.).
³ Department of Anasthesia, St. Michael's Hospital, and University of Toronto, Ontario, Canada (C.D.M.).
⁴ Institute of Life Science, Swansea University, United Kingdom (S.C.B.).
⁵ University of North Carolina School of Medicine, Chapel Hill, NC (J.B.).
⁶ HCA Midwest Health Heart and Vascular Institute, Kansas City, MO (S.M.).
⁷ Diabetes Center Bochum-Hattingen, St. Josef-Hospital, Ruhr-University Bochum, Germany (M.N.).
⁸ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Ontario, Canada (B.Z.).
⁹ Novo Nordisk A/S, Søborg, Denmark (H.B.-T., S.R., M.M.M.).
¹⁰ Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, MA (D.L.B.).

No abstract available

Keywords: diabetes mellitus; liraglutide.

Publication types